Trastuzumab-Doxorubicin Conjugate Provides Enhanced Anti-Cancer Potency and Reduced Cardiotoxicity

Journal of Cancer Therapy
doi 10.4236/jct.2013.41038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Scientific Research Publishing, Inc.

Related search

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Oncologist
Cancer ResearchMedicineOncology
2013English

An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

Circulation
Cardiovascular MedicinePhysiologyCardiology
2013English

Anthracycline- And Trastuzumab-Induced Cardiotoxicity: A Retrospective Study

Medical Oncology
MedicineCancer ResearchOncologyHematology
2016English

Trastuzumab in the Treatment of Metastatic Breast Cancer : Anticancer Therapy Versus Cardiotoxicity

Circulation
Cardiovascular MedicinePhysiologyCardiology
2000English

Doxorubicin Cardiotoxicity and Target Cells: A Broader Perspective

Cardio-Oncology
2016English

A Meta-Analysis of Incidence and Risk Factors of Trastuzumab-Induced Cardiotoxicity in Breast Cancer

Journal of Patient-Centered Research and Reviews
2015English

Aptamer–drug Conjugate: Targeted Delivery of Doxorubicin in a HER3 Aptamer-Functionalized Liposomal Delivery System Reduces Cardiotoxicity

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

Neuregulin1-ErbB Signaling in Doxorubicin-Induced Cardiotoxicity

2012English

Amelioration of Doxorubicin‑induced Cardiotoxicity by Resveratrol

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy